1159PPhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
C-C Lin,Matthew H. Taylor,Valentina Boni,Paal Brunsvig,Sarayut Lucien Geater,S Salvagni,P. Garrido Lopez,Mustafa Ozguroglu,Virote Sriuranpong,S. Ponce Aix,P A Ascierto,Angelica Fasolo,Ahmet Sezer,Dariusz M. Kowalski, J E Faris,Scott Cameron, J Mataraza, H Wu, V. Antona, M Ochoa de Olza ANNALS OF ONCOLOGY（2018）
AI 理解论文
溯源树
样例
